about
Molecular approaches and modern clinical strategies for the management of Helicobacter pylori infection in JapanStudy of infection strategies of Helicobacter pylori and host cell response against CagA oncoproteinHelicobacter pylori resistance to rifabutin in the last 7 years.Nordihydroguaiaretic Acid Disrupts the Antioxidant Ability of Helicobacter pylori through the Repression of SodB Activity In VitroRoles of oxidative stress in stomach disorders.Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies.BH3-only protein Bim is associated with the degree of Helicobacter pylori-induced gastritis and is localized to the mitochondria of inflammatory cells in the gastric mucosaCD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence.Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study.Sigma-2 receptor and progesterone receptor membrane component 1 (PGRMC1) are two different proteins: Proofs by fluorescent labeling and binding of sigma-2 receptor ligands to PGRMC1.Cystathionine β-synthase and PGRMC1 as CO sensors.Bile acids increase levels of microRNAs 221 and 222, leading to degradation of CDX2 during esophageal carcinogenesis.The tumor suppressor microRNA-29c is downregulated and restored by celecoxib in human gastric cancer cells.Development of a novel microRNA promoter microarray for ChIP-on-chip assay to identify epigenetically regulated microRNAs.Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells.Isolation and characterization of a cytotoxin produced by Plesiomonas shigelloides P-1 strain.Efficacy of 10-day Sitafloxacin-Containing Third-Line Rescue Therapies for Helicobacter pylori Strains Containing the gyrA Mutation.Mucosal expression of aquaporin-4 in the stomach of histamine type 2 receptor knockout mice and Helicobacter pylori-infected mice.Contribution of efflux pumps to clarithromycin resistance in Helicobacter pylori.Homology model of the DNA gyrase enzyme of Helicobacter pylori, a target of quinolone-based eradication therapy.Acid suppression by proton pump inhibitors enhances aquaporin-4 and KCNQ1 expression in gastric fundic parietal cells in mouse.Delayed gastric emptying and disruption of the interstitial cells of Cajal network after gastric ischaemia and reperfusion.Cell adherence-promoted activity of Plesiomonas shigelloides groEL.Invasive phenotype and apoptosis induction of Plesiomonas shigelloides P-1 strain to Caco-2 cells.Enteric Glial Dysfunction Evoked by Apolipoprotein E Deficiency Contributes to Delayed Gastric Emptying.Inhibiting xCT Improves 5-Fluorouracil Resistance of Gastric Cancer Induced by CD44 Variant 9 ExpressionEnhanced bacterial efflux system is the first step to the development of metronidazole resistance in Helicobacter pyloriFecA1, a bacterial iron transporter, determines the survival of Helicobacter pylori in the stomachTwo amino acids mutation of ferric uptake regulator determines Helicobacter pylori resistance to metronidazoleCAPZA1 determines the risk of gastric carcinogenesis by inhibiting Helicobacter pylori CagA-degraded autophagyNeutrophil-activating Protein Polymorphism of Helicobacter pylori Determines the Host Risk of DyspepsiaPrecision Medicine Approaches to Prevent Gastric CancerCancer Stem-Cell Marker CD44v9-Positive Cells Arise From Helicobacter pylori-Infected CAPZA1-Overexpressing CellsEnhancement of Amoxicillin Resistance after Unsuccessful Helicobacter pylori Eradication
P50
Q26824055-35BB5222-1D1F-4D4F-9D8B-FFB8EE569F39Q27022063-7FA077BB-286D-4D77-9A5C-B9C9BDD116B4Q35363984-0292C104-DA34-4AC9-AAE8-78C6AC779F28Q35475773-4499BCDE-AFB8-47E4-B4FC-DD5FF1071FDCQ35634421-4FA8BEFF-1CD7-438D-BF6D-32AA2FB711FCQ35806155-11042652-2A50-46AA-A0AA-23FFE23C6401Q36017091-8D7F966F-628F-43C8-A5C8-F48AE7B7B2E8Q37040620-F644FA2F-3210-4ED7-A56F-EB0E294A0B00Q37045762-194F566E-6DF5-4598-B4ED-FBFB01B3FC37Q38779118-72581422-2570-4582-84A6-78A9C7C902FFQ38938277-1C9E3790-9928-4489-B603-BA58BD41E5A9Q39112413-DA633F36-357B-46EA-97C7-46296E3F334BQ39273352-0189012E-4D7B-4D86-A535-9F6972E596D2Q39294397-17BF2E74-1800-4A33-9173-414E25B74233Q39841597-36143391-FD5B-4F74-B91E-13C1FA0730E3Q40510579-40E9FE85-B43F-4A87-89E6-1A9CA3385B17Q40892650-A62B8410-9219-4C19-BFFB-35CCEC04DE0CQ41592570-48A83087-4E91-42DF-89B6-CC56C1DB9CD3Q43002204-8939DF4C-F7CD-407A-991F-38F283BFE79CQ43002207-ACB6DA11-F9D4-4A70-B978-2FF3521BE7E4Q43076615-68C08C44-6A5F-43FF-8765-AFE1E8A63D11Q43205512-49E4824E-8924-4539-99F6-ED88A9E74DE6Q44403197-98B73F7D-39AC-47BC-9404-FF5639526BE2Q46824304-5D80F274-DC8F-4888-AC8B-448BFADEE701Q47446449-3E53290B-2BE5-474C-B402-7266AEA4F5D2Q58542499-FEA0D91A-362C-4997-8AF1-81F54175A309Q82830880-E0430679-1443-4976-89C9-C5A91C226DE2Q83242574-3DDD59BC-FB11-4B81-9077-F537C210CC97Q84343599-BBD9B706-64CC-44C2-93C2-11D29ED53B67Q91271434-2105FC77-3DED-405C-83AF-107DA283F94CQ92159183-13A3E143-DB87-49D3-BD4B-5276F43029AFQ92362249-8081A6A9-72F5-4F25-A8F2-65C8FAECB3C4Q92406722-55E37D64-3859-4FBB-B6A6-015887341590Q93572286-F514504B-582B-4FB3-9520-758577DFAAF2
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Hitoshi Tsugawa
@en
Hitoshi Tsugawa
@nl
type
label
Hitoshi Tsugawa
@en
Hitoshi Tsugawa
@nl
prefLabel
Hitoshi Tsugawa
@en
Hitoshi Tsugawa
@nl
P31
P496
0000-0002-4344-4475